Zyprexa: Difference between revisions
(23 pages) |
(Added categories) |
||
| Line 1: | Line 1: | ||
{{Wiki | {{Wiki | ||
| wiki_logo = | | wiki_logo = [[Image:NoLogoYet.png]] | ||
| wiki_URL = http://zyprexa.pbwiki.com | | wiki_URL = http://zyprexa.pbwiki.com | ||
| wiki_recentchanges_URL = No | | wiki_recentchanges_URL = No | ||
| Line 8: | Line 8: | ||
| wiki_editmode = LoginToEdit | | wiki_editmode = LoginToEdit | ||
| wiki_engine = Pbwiki | | wiki_engine = Pbwiki | ||
| wiki_maintopic = | | wiki_maintopic = Pharmaceuticals | ||
}} | }} | ||
==Description== | ==Description== | ||
{{ | For the past few years, there has been some controversy about the drug {{tag|Zyprexa}}. What we all know is that Zyprexa is an "atypical" neuroleptic (also known as an "anti-psychotic"), approved to treat schizophrenia and acute mania. At about $2.50/pill, it is a big money maker for Eli Lilly, somewhere on the order of $4 Billion a year. By themselves, these facts are not controversial. | ||
However, it seems that some internal memos indicate that Eli Lilly knew that the {{tag|drugs|drug}} raised the risk of {{tag|diabetes}} in patients and didn't act appropriately. They may have even misreported clinical trial data about blood-sugar risks to doctors. There is currently a class action lawsuit underway to hold Lilly accountable. These memos indicate that Lilly initiated an internal marketing campaign to willfully downplay these deleterious effects. | |||
However, it seems that some internal memos indicate that Eli Lilly knew that the drug raised the risk of diabetes in patients and didn't act appropriately. They may have even misreported clinical trial data about blood-sugar risks to doctors. There is currently a class action lawsuit underway to hold Lilly accountable. These memos indicate that Lilly initiated an internal marketing campaign to willfully downplay these deleterious effects. | |||
There may be other risks that the company knew about but was hiding. | There may be other risks that the company knew about but was hiding. | ||
| Line 22: | Line 20: | ||
Furthermore, Lilly has been training sales reps to instruct general practitioners to prescribe Zyprexa, off label, to elderly patients exhibiting general symptoms of dementia. These drugs are dangerous enough in the hands of specialists - general practitioners should not be trained by salespeople to prescribe such potent and dangerous psychopharmaceuticals. Lilly called this marketing initiative Viva Zyprexa, from which we have taken our satirical name for this campaign - Zyprexa Kills. | Furthermore, Lilly has been training sales reps to instruct general practitioners to prescribe Zyprexa, off label, to elderly patients exhibiting general symptoms of dementia. These drugs are dangerous enough in the hands of specialists - general practitioners should not be trained by salespeople to prescribe such potent and dangerous psychopharmaceuticals. Lilly called this marketing initiative Viva Zyprexa, from which we have taken our satirical name for this campaign - Zyprexa Kills. | ||
{{Size | {{Size | ||
| Line 28: | Line 25: | ||
| wiki_pages = 23 | | wiki_pages = 23 | ||
}} | }} | ||
[[Category:Medical]] | |||
Revision as of 22:16, 22 September 2009
| [{{{URL}}} {{{logo}}}] | [{{{URL}}} Zyprexa] [{{{recentchanges URL}}} Recent changes] [No WikiNode] [No About] [No Mobile URL] |
|---|---|
| Founded by: | |
| Status: | [[:Category:{{{status}}}|{{{status}}}]] |
| Language: | [[:Category:Wiki {{{language}}}|{{{language}}}]] |
| Edit mode: | [[:Category:{{{editmode}}}|{{{editmode}}}]] |
| Wiki engine: | [[:Category:{{{engine}}}|{{{engine}}}]] |
| Wiki license: | [[:Category:Wiki {{{license}}}|{{{license}}}]] |
| Main topic: | [[:Category:{{{maintopic}}}|{{{maintopic}}}]] |
Description
For the past few years, there has been some controversy about the drug Zyprexa. What we all know is that Zyprexa is an "atypical" neuroleptic (also known as an "anti-psychotic"), approved to treat schizophrenia and acute mania. At about $2.50/pill, it is a big money maker for Eli Lilly, somewhere on the order of $4 Billion a year. By themselves, these facts are not controversial.
However, it seems that some internal memos indicate that Eli Lilly knew that the drug raised the risk of diabetes in patients and didn't act appropriately. They may have even misreported clinical trial data about blood-sugar risks to doctors. There is currently a class action lawsuit underway to hold Lilly accountable. These memos indicate that Lilly initiated an internal marketing campaign to willfully downplay these deleterious effects.
There may be other risks that the company knew about but was hiding.
Incidentally, Lilly's second most profitable drugs treat diabetes.
Furthermore, Lilly has been training sales reps to instruct general practitioners to prescribe Zyprexa, off label, to elderly patients exhibiting general symptoms of dementia. These drugs are dangerous enough in the hands of specialists - general practitioners should not be trained by salespeople to prescribe such potent and dangerous psychopharmaceuticals. Lilly called this marketing initiative Viva Zyprexa, from which we have taken our satirical name for this campaign - Zyprexa Kills.
| Wiki size: | unknown size |